News
Atonco plays an active role in finding new collaborators who are highly experienced in their field of expertise and in establishing partnerships with various actors involved in the field of alphatherapy.
ATO-101™: A THERAPEUTIC ADVANCE FOR THE TREATMENT OF NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC)
Atonco is proud to announce that the preclinical and clinical study results have been published in the Cancers (MDPI) journal, highlighting the promising potential of its radiopharmaceutical ATO-101™ ([211At]At-girentuximab) in the alpha-immunotherapy treatment using astatine-211 of non-muscle-invasive bladder cancer (NMIBC) refractory to standard therapies, including BCG.
ATONCO AND GIP ARRONAX SIGN CONTRACT TO DEVELOP AN INNOVATIVE RADIOPHARMACEUTICAL FOR ALPHA RADIOTHERAPY
Atonco and GIP ARRONAX (Saint Herblain, France) have joined forces to take the next step in the implementation of alpha-immunotherapy for cancer.
ATONCO AND UNIVERSITY OF MICHIGAN ANNOUNCE COLLABORATION ON PHASE 1-2a CLINICAL STUDY OF ATO-101™
Atonco, a French biotechnology company, and University of Michigan today announced a collaborative agreement to conduct a Phase 1-2a clinical study evaluating Atonco’s ATO-101™ ([211At] At-anti-CA-IX antibody) targeted alpha therapy candidate in non-muscle invasive bladder cancer (NMIBC).
ATONCO AND MINERVA IMAGING JOIN FORCES IN TARGETING BLADDER CANCER
ATONCO (Saint Herblain, France) and Minerva Imaging (Oelstykke, Denmark), are pleased to announce a close collaboration to combine their strengths to fight bladder cancer.
TARGETED ALPHA THERAPY CANDIDATE : BLADDER CANCER STUDY COMPLETES ENROLMENT
Telix (Melbourne, Australia) and Nantes-based ATONCO S.A.S. (‘ATONCO’) today announced that the final patient has been dosed in a Phase I study of TLX250-CDx in patients with non-muscle invasive bladder cancer (NMIBC) at the Institut de Cancérologie de l’Ouest (ICO) in St Herblain, France.
IONETIX AND ATONCO SIGN PARTNERSHIP AGREEMENT TO FIGHT BLADDER CANCER
Atonco (Nantes-Saint Herblain, France) and Ionetix (Lansing, MI, USA) have signed a partnership agreement to ensure the manufacturing and GMP supply of the radiopharmaceutical required for the successful completion of Atonco’s clinical studies and commercialization in the United States.
FIRST PATIENT DOSED IN FEASIBILITY STUDY OF TARGETED ALPHATHERAPY FOR BLADDER CANCER
Telix Pharmaceuticals and ATONCO are pleased to announce that the first patient has been treated in the PERTINENCE feasibility study in patients with non-muscle-invasive bladder cancer (NMIBC) at the Institut de Cancérologie de l’Ouest (ICO) in St Herblain, France.
ATONCO AND THE INSTITUT DE CANCÉROLOGIE DE L’OUEST – NANTES ANGERS (ICO) CLINICAL PARTNERS IN THE FIGHT AGAINST CANCER
ATONCO announced today that it has entered into a clinical research partnership agreement with the Institut de Cancérologie de l’Ouest (ICO Nantes Angers) for the clinical study using an alpha emitting radionuclide for the treatment of non-muscle-invasive bladder cancer resistant to standard therapies.
ATONCO ANNOUNCES THE APPOINTMENT OF ADRIEN REYMOND AS DIRECTOR OF REGULATORY AFFAIRS AND QUALITY ASSURANCE
Atonco announced today that Adrien Reymond, PharmD, B.Eng and EMBA candidate, will lead pharmaceutical, regulatory affairs and quality assurance to be in compliance with Good Clinical Practices (GCP) and preparation for ISO 9001:2015 certification.
ATONCO ANNOUNCES THE APPOINTMENT OF SYLVAIN FANIER AS NEW PRESIDENT OF ATONCO
Atonco announced today that Sylvain Fanier, Msc. EMBA, will succeed Professor Jean-François Chatal as President.